AbbVie Inc.

ABBVleader

AbbVie is a global biopharmaceutical company that was spun off from Abbott Laboratories in 2013. While Humira was once the world's best-selling drug, AbbVie has successfully navigated its patent cliff with Skyrizi and Rinvoq, which are on track to exceed Humira's peak revenue combined.

共有:

⇄ Compare

製品と売上

製品別売上シェア

売上内訳 ($56.3B)

静的データ（リアルタイム財務ロード中…）

Immunology (45%)

Aesthetics/Neuroscience (25%)

Oncology (15%)

Eye Care & Other (15%)

セグメント構成と主要顧客

製品詳細

Skyrizi / Rinvoq35%

Next-generation immunology biologics replacing Humira revenue

Humira20%

Anti-TNF biologic for rheumatoid arthritis and autoimmune diseases (declining post-LOE)

Botox / Aesthetics25%

Allergan aesthetics portfolio including Botox, Juvederm, and CoolSculpting

サプライチェーン関係

競合他社

Eli Lilly and Company

Immunology and oncology drugs

影響: Key therapeutic competitor

Regeneron Pharmaceuticals

Dupixent vs Skyrizi/Rinvoq

影響: Direct immunology competition

Pfizer Inc.

Broad pharmaceutical portfolio overlap

影響: Major pharma rival

マクロ・市場概況

제약 / 바이오セクターニュース

GLP-1 메가트렌드 + AI 신약개발 + 저평가 바이오 기관 매집

GLP-1 시장 규모 (2030E)

$150B

mRNA 암백신 임상 성공률

+49% 재발 위험 감소

AI 신약개발 단계

임상 2상 진입

PFE/MRNA 52주 변화

-30% ~ -45%

次の主要イベント

◆LLY Orforglipron(경구용 GLP-1) 3상 결과 (2026.Q2)◆MRNA 암백신 FDA BLA 제출 예정◆REGN EYLEA HD 유럽 허가 결과

AI分析

AbbVie Inc.のAIサプライチェーン分析を受けるには「AI分析を取得」をクリックしてください。

企業情報

本社所在地

North Chicago, Illinois, USA

設立

2013

従業員数

50,000+

ウェブサイト

abbvie.com

セクター概況 — 제약 / 바이오

セクターニュース